

Raffaele Ratta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3566305/publications.pdf>

Version: 2024-02-01

43
papers

609
citations

471061

17
h-index

642321

23
g-index

43
all docs

43
docs citations

43
times ranked

1294
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study. <i>Current Oncology</i> , 2022, 29, 945-955.	0.9	6
2	REchallenge of NIVOLUMAB (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	7
3	Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. <i>Tumori</i> , 2021, 107, 542-549.	0.6	4
4	Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 671969.	1.3	7
5	Integrated transcriptionalâ€phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. <i>Clinical and Translational Medicine</i> , 2021, 11, e434.	1.7	3
6	KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 3291-3299.	1.1	22
7	Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects. <i>European Journal of Cancer</i> , 2021, 159, 87-97.	1.3	6
8	PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 549-560.	2.0	36
9	Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1475.	1.8	25
10	Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?. <i>Journal of Clinical Medicine</i> , 2020, 9, 930.	1.0	25
11	Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. <i>Cancers</i> , 2019, 11, 980.	1.7	18
12	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. <i>European Urology Oncology</i> , 2019, 2, 699-707.	2.6	38
13	Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 291-298.	0.9	30
14	The role of metastasectomy in advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 603-611.	1.1	7
15	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. <i>Cancers</i> , 2019, 11, 223.	1.7	18
16	Side effects of immunotherapy: a constant challenge for oncologists. <i>Current Opinion in Oncology</i> , 2019, 31, 280-285.	1.1	19
17	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 42-45.	0.6	20
18	Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e735-e742.	0.9	14

#	ARTICLE	IF	CITATIONS
19	Combination therapies for patients with metastatic renal cell carcinoma. <i>Lancet Oncology</i> , The, 2018, 19, 281-283.	5.1	4
20	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. <i>The INVIDia study. Immunotherapy</i> , 2018, 10, 1229-1239.	1.0	38
21	TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery. <i>Tumori</i> , 2018, 104, 401-405.	0.6	10
22	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e945-e951.	0.9	30
23	Does Fâ€18 ^FDG</sup>â€PET</sup> still play a role in metastatic renal cell carcinoma?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 250-251.	0.9	0
24	What advances have been made in immune-therapy for renal cell carcinoma?. <i>Future Oncology</i> , 2017, 13, 665-668.	1.1	0
25	Multimodal treatment of advanced renal cancer in 2017. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1395-1402.	1.3	23
26	Castration-naïve metastatic prostate cancer: reshaping old paradigms. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 879-881.	1.1	3
27	Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?. <i>Drugs in R and D</i> , 2017, 17, 461-467.	1.1	5
28	Personalized therapy in renal cell carcinoma: are the different tyrosine kinase inhibitors the same for any patient?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 5-7.	0.4	3
29	Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. <i>Oncotarget</i> , 2017, 8, 100708-100716.	0.8	32
30	Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2167-2172.	2.0	15
31	Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. <i>Therapeutic Advances in Urology</i> , 2016, 8, 319-326.	0.9	25
32	Immunotherapy advances in uro-genital malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 52-64.	2.0	19
33	Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 323-330.	1.4	13
34	Improved quality of life is the way to longer life. <i>Lancet Oncology</i> , The, 2016, 17, 862-863.	5.1	5
35	Evolving treatment landscape in metastatic renal cell carcinoma: where are we now?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 133-135.	1.1	1
36	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 48-55.	0.9	14

#	ARTICLE	IF	CITATIONS
37	Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. <i>BJU International</i> , 2015, 115, 764-771.	1.3	17
38	Predicting Molecular Models: Where Are We Going?. <i>EBioMedicine</i> , 2015, 2, 1594-1595.	2.7	0
39	Pazopanib and pancreatic toxicity: a case report. <i>BMC Research Notes</i> , 2015, 8, 196.	0.6	9
40	Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 265.e15-265.e21.	0.8	6
41	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015, 11, 2881-2891.	1.1	12
42	Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanib. <i>Tumori</i> , 2014, 100, e59-62.	0.6	1
43	Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients. <i>European Journal of Cancer</i> , 2013, 49, 1501-1508.	1.3	19